Drugs / hMSCs
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02962661 | Jul 2020 → Jul 2026 overdue | cancer, cardiomyopathy, heart failure, hematopoietic and lymphoid cell neoplasm | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT03137199 | Jun 2017 → Mar 2020 | asthma | Marilyn Glassberg | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT02625246 | Feb 2016 → May 2019 | bronchiectasis | Marilyn Glassberg | Completed | No outcome recorded |
| Phase 1 | NCT02408432 | Jan 2016 → Dec 2021 | cardiomyopathy, heart failure | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hMSCs | “To demonstrate the safety of allogeneic human mesenchymal stem cells (hMSCs) administered by intravenous infusion and transendocardial injection in patients with left...” NCT02962661 ↗3“allogeneic human mesenchymal stem cells (hMSCs) administered by intravenous infusion” NCT02408432 ↗ |
| Modality | Cell therapy | “Bone marrow derived mesenchymal stem cells (MSCs)” NCT02408432 ↗ |
| Route | Intravenous | “administered via peripheral intravenous infusion” NCT02625246 ↗ |